Effect of sugammadex on bronchial smooth muscle function in rats

Journal of Smooth Muscle Research

Volumn 48, Issue 2-3, 2012, Pages 59-64

  Yoshioka, Naoki ^a   Hanazaki, Motohiko ^a   Fujita, Yoshihisa ^a   Nakatsuka, Hideki ^a   Katayama, Hiroshi ^a   Chiba, Yoshihiko ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Adverse effect; Bronchial smooth muscle; Rat; Sugammadex

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; GAMMA CYCLODEXTRIN DERIVATIVE; SUGAMMADEX;

ANIMAL; ARTICLE; BRONCHUS; DRUG EFFECT; DRUG SCREENING; IN VITRO STUDY; MALE; MUSCLE CONTRACTION; RAT; SMOOTH MUSCLE; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; BRONCHI; CHOLINERGIC AGONISTS; DRUG EVALUATION, PRECLINICAL; GAMMA-CYCLODEXTRINS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RATS; RATS, WISTAR;

EID: 84868663611     PISSN: 09168737     EISSN: 18848796     Source Type: Journal    
DOI: 10.1540/jsmr.48.59     Document Type: Article

References (11)

1. Amao, R., Zornow, M.H., Cowan, R.M., Cheng, D.C.H. and Allard, M. (2007). Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology 107: A1582.
2. Chiba, Y., Arima, J., Sakai, H. and Misawa, M. (2008). Lovastatin inhibits bronchial hyperresponsiveness by reducing RhoA signaling in rat allergic asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L705-L713.
3. Chiba, Y., Takada, Y., Miyamoto, S., Mitsui-Saito, M., Karaki, H. and Misawa, M. (1999). Augmented acetylcholine-induced, Rho-mediated Ca2+ sensitization of bronchial smooth muscle contraction in antigeninduced airway hyperresponsive rats. Br. J. Pharmacol. 127: 597-600.
4. Hanazaki, M., Chiba, Y., Yokoyama, M., Morita, K., Kohjitani, A., Sakai, H. and Misawa, M. (2008). Y-27632 augments the isoflurane-induced relaxation of bronchial smooth muscle in rats. J. Smooth Muscle Res. 44: 189-193.
5. Martin, J.G., Duguet, A. and Eidelman, D.H. (2000). The contribution of airway smooth muscle to airway narrowing and airway hyperresponsiveness in disease. Eur. Respir. J. 16: 349-354.
6. Naguib, M. (2007). Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth. Analg. 104: 575-581.
7. Plaud, B., Meretoja, O., Hofmockel, R., Raft, J., Stoddart, P.A., van Kuijk, J.H., Hermens, Y. and Mirakhur, R.K. (2009). Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 110: 284-294.
8. Ploeger, B.A., Smeets, J., Strougo, A., Drenth, H.J., Ruigt, G., Houwing, N. and Danhof, M. (2009). Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology 110: 95-105.
9. Seow, C.Y., Schellenberg, R.R. and Pare, P.D. (1998). Structural and functional changes in the airway smooth muscle of asthmatic subjects. Am. J. Respir. Crit. Care Med. 158: S179-S186.
10. Sparr, H.J., Vermeyen, K.M., Beaufort, A.M., Rietbergen, H., Proost, J.H., Saldien, V., Velik-Salchner, C. and Wierda, J.M. (2007). Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology 106: 935-943.
11. Zhang, M.-Q. (2003). Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drug Future 28: 347-354.